Fertility Clinic Marketing Compliance: IVF Success Rate Claims, SART Disclosure, and the Specific Rules That Apply

Fertility and IVF clinic marketing operates under some of the most specific success-rate reporting rules in healthcare, shaped by the Fertility Clinic Success Rate and Certification Act of 1992 and ongoing SART (Society for Assisted Reproductive Technology) reporting. Add FTC scrutiny of outcome claims, state-specific rules on fertility advertising, and the emerging complexity of donor/surrogacy marketing, and fertility clinic marketing has a compliance profile unlike most other specialties.

IVF success rate reporting rules

The Fertility Clinic Success Rate and Certification Act requires IVF clinics to report success rates to the CDC, which publishes national data. SART publishes its own member clinic data. Marketing considerations:

• Clinics should accurately represent their success rates consistent with SART/CDC reporting.
• Success rate presentations should specify denominators (per cycle started, per transfer, per retrieval, live birth rate, pregnancy rate).
• Comparing clinic rates without appropriate context (patient age distribution, case complexity) creates misleading comparison issues.
• Historical rates require time-period disclosure.

Problematic marketing patterns

Pattern 1: Cherry-picked success rates

Selecting the most favorable age group or cycle type to advertise without clear disclosure of what specific rate you’re presenting creates deceptive-marketing exposure. The clinic may have legitimate reasons for specific patient populations but marketing needs context.

Pattern 2: Outcome guarantees

“Money-back if no baby” programs exist but face careful regulatory review. Their compliance depends on clear disclosure of exclusions, eligibility, and refund mechanics. Broad outcome guarantees without this framing create exposure.

Pattern 3: “Leading” or “best” claims

Comparative claims between fertility clinics need substantiation. Age-adjusted outcome comparisons are complex; “highest success rate” claims are typically unsubstantiable without specific evidence.

Pattern 4: Egg freezing marketing

Egg freezing marketing faces specific considerations:

• Future-pregnancy outcome marketing based on egg freezing is speculative - actual outcomes depend on future uses that have not yet occurred.
• “Insurance policy” framing of egg freezing has been criticized by FTC-adjacent commentary.
• Employer-benefit egg-freezing marketing has its own specific framing considerations.

Pattern 5: Donor gamete and embryo marketing

Donor marketing (egg donors, sperm donors, embryo donation) has specific rules:

• Donor recruitment marketing has FDA and state considerations.
• Matching service marketing faces consumer protection scrutiny.
• Outcome claims for specific donor categories need substantiation.

Pattern 6: Gestational surrogacy

Surrogacy marketing varies by state legality and has specific federal and state rules beyond standard healthcare marketing. International surrogacy marketing adds jurisdiction complexity.

Pattern 7: LGBTQ+ family-building marketing

Marketing to LGBTQ+ patients requires accurate description of services, costs, and legal considerations. Varied state laws on parental rights in assisted reproduction affect what outcomes are achievable in specific states.

Emerging fertility-tech marketing

• PGT (preimplantation genetic testing).Specific clinical-utility claims require substantiation; expanded indication marketing has drawn specific attention.
• Mitochondrial replacement therapy.Marketing for non-FDA-approved procedures.
• Fertility-awareness apps and wearables.Some are FDA-regulated; marketing should reflect accurate regulatory status.
• AI-assisted embryo selection. Claims about improved outcomes need substantiation.

Financing and pricing marketing

IVF pricing marketing is a specific consumer-protection focus:

• “$X per cycle” marketing needs clear disclosure of medications, monitoring, facility fees, and other costs.
• Package programs (multi-cycle, shared-risk) have specific disclosure requirements.
• Financing partnership disclosure for loan programs.
• Insurance-coverage claims need accuracy about what insurance typically covers vs what’s out-of-pocket.

Compliant fertility marketing framework

1. Accurate success rate presentation. Cite specific SART-reported rates with appropriate age and denominator context.
2. Service-first marketing. Describe the clinical approach, patient experience, and team rather than leading with outcome claims.
3. Honest evidence framing. Success depends on many factors; marketing that acknowledges this is both honest and compliant.
4. Financial transparency. Clear disclosure of what pricing includes and what typical total costs look like.
5. Appropriate emotional tone. Fertility is emotionally heightened; marketing should respect that without exploitation.
6. Inclusive and accurate family-building framing.LGBTQ+, single-parent, and non-traditional family building marketing should be accurate about what’s achievable.

Frequently asked questions

Can I market our clinic as having higher success rates than average?

With accurate substantiation and appropriate context. Cite specific SART-reported rates with the specific metric and age-group. Avoid “higher than average” without specific benchmark citation.

How should I handle patient stories and testimonials?

With HIPAA authorization and typical-experience framing. Fertility success stories are emotionally powerful marketing but carry disease-treatment claim exposure if tied to specific outcome promises.

What about shared-risk and money-back programs?

These programs can be structured compliantly but need specific disclosure of eligibility, exclusions, refund mechanics, and actual outcomes. They’ve drawn state consumer protection attention when disclosure is inadequate.

Can I market to specific age groups?

Yes, with accuracy. Age-specific fertility marketing should reflect accurate age-related outcome considerations. Urgent framing of fertility decline should be supported by accurate clinical context, not scare-based marketing.

What about international patient marketing?

International patient marketing adds medical tourism considerations on top of fertility-specific rules. State licensure requirements for clinical care remain regardless of patient origin.

Do I need to report specific outcome data by request?

SART reporting is the primary regulatory framework. Patient requests for specific outcome data should be handled consistent with your regular clinical communication practices.